Positive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of Study

Positive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of Study
Celgene Corporation has reported positive interim results from a Phase 1b clinical trial assessing the effects of oral GED-0301 (mongersen) on endoscopic and clinical outcomes in patients with active Crohn’s disease. The trial aims to provide further data of GED-0301 activity in a difficult-to-treat, moderate-to-severe and very diverse patient population, including patients with endoscopically confirmed mucosal damage at entry, those who had previous surgeries, those who have taken biologics or are biologic naïve,  and patients with a diagnosis of ileitis, ileocolitis or colitis. Titled "
Subscribe or to access all post and page content.